Clearant Sets New Record with November Sterile Implant Sales.

Fourth Quarter Sales Already Greater Than That of Previous Quarter

LOS ANGELES -- The second graph, second sentence should read: 73 Clearant Process Sterile Implants were sold xxx (sted 65 Clearant Process Sterile Implants were sold xxx), and the third sentence should read: xxx sales have already exceeded total third quarter sales by about 40 percent. (sted xxx sales have already exceeded total third quarter sales by about 25 percent.)

The corrected release reads:

Clearant Sets New Record with November Sterile Implant Sales

Fourth Quarter Sales Already Greater Than That of Previous Quarter

Clearant, Inc. (OTCBB:CLRI) today announced that it sold 47 Clearant Process[R] Sterile Implant cervical spinal and soft tissue allografts directly to surgeons, hospitals and clinics in November. Nearly doubling sales from the previous month, November implant sales were markedly higher than during any other month since Clearant launched its direct sales initiative in June 2006.

Clearant's direct sales figures have steadily increased every month since it made Clearant Process Sterile Implants available directly to surgeons and surgery centers around the country. 73 Clearant Process Sterile Implants were sold directly during the first two months of the fourth quarter as compared to 52 sold in all of the third quarter. During the first two months of the fourth quarter, sales have already exceeded total third quarter sales by about 40 percent.

"Surgeons and clinics across the country are making patient safety their highest priority by choosing to provide sterile implants," said Clearant Chief Executive Officer Alain Delongchamp. "Clearant is on pace to sell approximately 100 implants during the current quarter, which would represent an increase of 100 percent over third quarter sales which was our first full quarter of operations under the new direct distribution initiative."

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company began to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. Clearant also has 10 license and service agreements with tissue banks. To date more than 9,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, acceptance and success of our direct distribution of allografts, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.